-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (600276.SH): SHR-4595 for injection obtained approval notice for drug clinical trials

Zhitongcaijing·09/21/2026 08:57:03
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” on SHR-4595 for injectable use, and will conduct clinical trials in the near future.

SHR-4595 for injection is a therapeutic biological product independently developed by the company. It can specifically bind to tumor cell surface antigens to kill tumor cells and is intended to treat advanced malignant solid tumors. According to inquiries, a domestic and foreign drug with the same target as this product has been approved for marketing. Up to now, the total R&D investment for SHR-4595 related projects for injectable use is about 16.4 million yuan (unaudited).